AnaptysBio

USA

AnaptysBio

AnaptysBio is a US-based company focused on the use of somatic hypermutation (SHM) for antibody discovery and optimization.

AnaptysBio is a US-based company focused on the use of somatic hypermutation (SHM) for antibody discovery and optimization. 

The company is currently developing a pipeline of novel therapeutic antibody candidates, including differentiated programs in cancer immunotherapy, inflammation, fibrosis, muscle wasting disorders and antibody-drug conjugate applications. 

AnaptysBio’s proprietary SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation in mammalian cells to generate high affinity antibodies, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.  By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, stability, function, cross-reactivity, epitope diversity and manufacturability.

In March 2014 AnaptysBio announced a strategic immuno-oncology collaboration with fellow USA-based Tesaro (Nasdaq: TSRO), an oncology-focused biopharmaceutical company, which could lead to payments of more than $340 million to the former.


Latest Articles

Back to top